Li Xinhui, Zhang Jisheng, Wang Jianmin, Long Wenzhang, Liang Xushan, Yang Yang, Gong Xue, Li Jie, Liu Longjin, Zhang Xiaoli
Department of Microbiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Front Microbiol. 2024 Mar 5;15:1210313. doi: 10.3389/fmicb.2024.1210313. eCollection 2024.
Isolates coproducing serine/metallo-carbapenems are a serious emerging public health threat, given their rapid dissemination and the limited number of treatment options. The purposes of this study were to evaluate the antibacterial activity of novel β-lactam-β-lactamase inhibitor combinations (BLBLIs) against carbapenem-resistant (CRKP) coproducing metallo-β-lactamase and serine-β-lactamase, and to explore their effects in combination with aztreonam, meropenem, or polymyxin in order to identify the best therapeutic options. Four CRKP isolates coproducing carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM) were selected, and a microdilution broth method was used to determine their susceptibility to antibiotics. Time-kill assay was used to detect the bactericidal effects of the combinations of antibiotics. The minimum inhibitory concentration (MIC) values for imipenem and meropenem in three isolates did not decrease after the addition of relebactam or varbobactam, but the addition of avibactam to aztreonam reduced the MIC by more than 64-fold. Time-kill assay demonstrated that imipenem-cilastatin/relebactam (ICR) alone exerted a bacteriostatic effect against three isolates (average reduction: 1.88 log CFU/mL) and ICR combined with aztreonam exerted an additive effect. Aztreonam combined with meropenem/varbobactam (MEV) or ceftazidime/avibactam (CZA) showed synergistic effects, while the effect of aztreonam combined with CZA was inferior to that of MEV. Compared with the same concentration of aztreonam plus CZA combination, aztreonam/avibactam had a better bactericidal effect (24 h bacterial count reduction >3 logCFU/mL). These data indicate that the combination of ATM with several new BLBLIs exerts powerful bactericidal activity, which suggests that these double β-lactam combinations might provide potential alternative treatments for infections caused by pathogens coproducing-serine/metallo-carbapenems.
同时产生丝氨酸/金属碳青霉烯酶的菌株是一种严重且新出现的公共卫生威胁,鉴于其迅速传播且治疗选择有限。本研究的目的是评估新型β-内酰胺-β-内酰胺酶抑制剂组合(BLBLIs)对同时产生金属β-内酰胺酶和丝氨酸β-内酰胺酶的耐碳青霉烯肺炎克雷伯菌(CRKP)的抗菌活性,并探索它们与氨曲南、美罗培南或多粘菌素联合使用的效果,以确定最佳治疗方案。选择了4株同时产生碳青霉烯酶(KPC)和新德里金属β-内酰胺酶(NDM)的CRKP菌株,采用微量肉汤稀释法测定它们对抗生素的敏感性。采用时间杀菌试验检测抗生素组合的杀菌效果。在三株菌株中,添加瑞来巴坦或瓦博巴坦后,亚胺培南和美罗培南的最低抑菌浓度(MIC)值并未降低,但氨曲南添加阿维巴坦后MIC降低了64倍以上。时间杀菌试验表明,亚胺培南-西司他丁/瑞来巴坦(ICR)单独使用对三株菌株发挥抑菌作用(平均降低:1.88 log CFU/mL),ICR与氨曲南联合使用发挥相加作用。氨曲南与美罗培南/瓦博巴坦(MEV)或头孢他啶/阿维巴坦(CZA)联合显示协同作用,而氨曲南与CZA联合的效果不如MEV。与相同浓度的氨曲南加CZA组合相比,氨曲南/阿维巴坦具有更好的杀菌效果(24小时细菌计数减少>3 logCFU/mL)。这些数据表明,氨曲南与几种新型BLBLIs联合具有强大的杀菌活性,这表明这些双β-内酰胺组合可能为同时产生丝氨酸/金属碳青霉烯酶的病原体引起的感染提供潜在的替代治疗方法。